Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CUE-400
- Development stage
- Preclinical
- Lead developer
- Cue BioPharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
CUE-400 is an investigational engineered biologic being developed by Cue BioPharma for the treatment of autoimmune and inflammatory diseases. Developed using the company's proprietary platform technology (such as the Immuno-STAT platform), CUE-400 is designed to selectively target and modulate FOXP3+ regulatory T cells (Tregs). The mechanism aims to restore immune homeostasis and promote immune tolerance by specifically engaging Treg populations, thereby suppressing pathological immune responses without the broad immunosuppression associated with conventional therapies. As of early 2026, the candidate remains in the early development pipeline at Cue BioPharma.
Beyond the preview
Go deeper on CUE-400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CUE-400.